T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting th

T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus

T2 Biosystems, Inc.

Thu, February 4, 2021, 10:05 PM·5 min read

TTOO

+7.14%

Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is capable of detecting the Brazil (P.1) variant of the SARS-CoV-2 virus, which was recently confirmed to be present in the United States.

“We continue to actively monitor new variants of the COVID-19 virus to confirm that our technology remains a useful and reliable diagnostic tool for the many health care systems and people that need it during this time,” said T2 Biosystems’ President and CEO, John Sperzel.